Click Therapeutics

Develops software as prescription medical treatments

New York City, New York, United States

About Click Therapeutics

Click Therapeutics develops software applications that function as prescription medical treatments for patients with various health conditions. These digital therapeutics are designed to change cognitive and neurobehavioral mechanisms related to diseases, and they are tested through rigorous randomized controlled trials to ensure safety and effectiveness. After validation, the company seeks FDA clearance to market these applications as class II medical devices. Unlike traditional pharmaceuticals, Click Therapeutics' products are prescribed by physicians and reimbursed by payers, allowing for a unique revenue model. A notable collaboration with Boehringer Ingelheim aims to create a digital therapeutic for schizophrenia, highlighting the potential of this approach in healthcare. The goal of Click Therapeutics is to provide effective digital solutions for patients with unmet medical needs, continuously improving their applications using real-world evidence.

New York City, New YorkHeadquarters
2012Year Founded
$93.9MTotal Funding
DEBTCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Company Match
Unlimited Paid Time Off
Flexible Work Arrangement
Stock Options
Performance Bonus
Fertility Treatment Support
Professional Development Budget
Commuter Benefits

Risks

Increased competition from digital therapeutic companies may impact market share.
Regulatory changes could affect approval processes for new digital therapeutics.
Integration challenges from acquisitions may delay new product development.

Differentiation

Click Therapeutics specializes in software as medical treatments for unmet medical needs.
Their Clickometrics® platform personalizes user experience to optimize engagement and outcomes.
Partnership with Boehringer Ingelheim highlights their collaborative approach in digital therapeutics.

Upsides

FDA clearance of Rejoyn™ boosts credibility in digital therapeutics for mental health.
Acquisition of Better Therapeutics expands Click's reach into cardiometabolic diseases.
$20 million financing from HSBC supports expansion and development initiatives.

Funding

Total raised$93.94 M
Latest valuation$260.00 M
StageDEBT